|
NEJM Trial - proportional hazard assumption
|
|
12
|
264
|
December 1, 2025
|
|
Omission of *absolute* risk reduction from NEJM Editorial on PSA testing
|
|
14
|
399
|
November 27, 2025
|
|
Rarity Roulette: A simulator for estimating hypothetical outcomes spreads for mass screenings
|
|
2
|
76
|
November 20, 2025
|
|
Individual response
|
|
266
|
48548
|
November 17, 2025
|
|
Feedback on BayeScores: A Bayesian AFT Mixture Cure Model for Quantifying Clinical Benefit
|
|
3
|
98
|
November 11, 2025
|
|
The rooster's crowing
|
|
0
|
106
|
October 20, 2025
|
|
When and why (not) to worry about the PO assumption
|
|
4
|
578
|
October 9, 2025
|
|
Fine-Gray vs Cause-Specific Cox Regression
|
|
0
|
93
|
September 11, 2025
|
|
Randomized non-comparative trials: an oxymoron?
|
|
64
|
4151
|
September 3, 2025
|
|
Table 2 Fallacy?: Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
|
|
32
|
4213
|
August 12, 2025
|
|
Causal inferences from RCTs- could “toy” clinical examples promote understanding?
|
|
17
|
2366
|
August 4, 2025
|
|
Accounting for period effect in crossover studies with washout
|
|
0
|
61
|
July 2, 2025
|
|
Why the Non-Reproducibility of Acute Care RCT? The CAP studies
|
|
6
|
186
|
May 8, 2025
|
|
Biobanks, data dredging and science-by-press-release
|
|
4
|
124
|
April 30, 2025
|
|
Lest we forget: “Epidemiology faces its limits”- 30 years later…
|
|
19
|
1329
|
April 3, 2025
|
|
Marginalizing predictions over categories of continuous predictors for lay audience presentations
|
|
5
|
465
|
January 28, 2025
|
|
Summary table of different Cox PHM models to compare them
|
|
7
|
1031
|
December 23, 2024
|
|
Interrupted Time Series, estimates before and after jump
|
|
2
|
742
|
November 23, 2024
|
|
Non Inferiority vs Non significant
|
|
17
|
1641
|
December 19, 2024
|
|
Least damaging way to convert model predictions to scores
|
|
8
|
746
|
November 29, 2024
|
|
Advice for appropriate causal model and analysis method
|
|
13
|
1988
|
November 19, 2024
|
|
Overall survival vs disease-free survival and other surrogate endpoints
|
|
6
|
8660
|
November 5, 2024
|
|
Interpreting the coefficient of a log transformed dependent variable
|
|
2
|
902
|
September 11, 2024
|
|
Use of percentage change in clinical trials
|
|
17
|
9375
|
July 22, 2024
|
|
Evaluating seizures in open-label studies
|
|
8
|
1321
|
July 21, 2024
|
|
Appropriate to do lasso, then standard glm using variables with non-zero coef. from lasso?
|
|
1
|
894
|
July 2, 2024
|
|
Estimands from zero-inflated regression model
|
|
9
|
1633
|
June 20, 2024
|
|
ITT analysis under equally high non-adherence in both arms in RCT
|
|
4
|
1048
|
June 9, 2024
|
|
Can we think of competing-event as another form of non-event in terms of utility?
|
|
0
|
1079
|
April 21, 2024
|
|
Is Lithium Equivalent to Lecanemab in Slowing cognitive decline in Alzheimer's Disease?
|
|
0
|
1122
|
February 23, 2024
|